Interleukin (IL-)18 is an activator of NK cells and a co-inducer of Th 1 cytokines, sharing structural features with the IL-1 family of proteins. Unlike most other cytokines, IL-18 and IL-1 lack a signal peptide, have an all -pleated sheet structure and are synthesized as biologically inactive precursors (pro-IL-18 and pro-IL-1 ). These precursors are cleaved by caspase-1 (IL-1 -converting enzyme, ICE) to form the biologically active mature cytokines. Direct expression of mature recombinant human IL-18 in E. coli resulted in a partially active cytokine. We tested the possibility that correct folding of huIL-18 requires its prior synthesis as pro-IL-18. Because caspase-1 is not readily available, we constructed an expression vector encoding human pro-IL-18 in which the caspase-1 cleavage site was mutated into a factor Xa site. To facilitate purification, the mutated pro-IL-18 cDNA was fused in frame to a glutathione-S-transferase (GST) coding sequence. The GST-pro-IL-18 fusion protein was expressed in E. coli, captured on glutathione agarose and mature human IL-18, exhibiting high biological activity was released upon cleavage with factor Xa. This result indicates that correct folding of huIL-18 occurs at the level of pro-IL-18 and provides a practical way to produce biologically active huIL-18.
Interleukin (IL-)18, initially described as an interferon (IFN-)-inducing factor, is a recently characterized cytokine that shares structural features with the IL-1 family of proteins. [1] [2] [3] [4] IL-18 was first purified and subsequently cloned from the livers of mice treated with heat-inactivated Propionbacterium acnes followed by lipopolysaccharide (LPS).
2, 5 Cloning of human IL-18 has also been described. 3 Like IL-12, IL-18 is produced by activated macrophages such as liver Kupffer cells and other resident macrophages. 3 IL-18 is an early inducer of the Th 1 response, co-stimulating the production of IFN-, as well as TNF-, granulocyte-macrophage colonystimulating factor and IL-2. 6 In addition, it potentiates anti-CD3-induced T cell proliferation and increases natural killer cell cytotoxicity by augmenting the expression of Fas ligand. 6, 7 Unlike most other cytokines, which exhibit a four-helix bundle structure, IL-18 and IL-1 have an all -pleated sheet structure. 7 The biosynthesis of IL-18 is similar to that of IL-1 , as IL-18 is first synthesized as a biologically inactive precursor (pro-IL-18), lacking a signal peptide. 3 The IL-1 and IL-18 precursors are cleaved by caspase-1 (IL-1 -converting enzyme, or ICE), after an aspartic acid residue in the P1 position. The resulting mature cytokines are subsequently released from the cell. 8, 9 Studies in caspase-1-deficient mice demonstrated the important role of mature IL-18 as an inducer of IFN-and Th 1 responses. Injection of P. acnes into caspase-1-deficient mice, followed by LPS challenge resulted in low levels of circulating IFNcompared with wild-type mice. [8] [9] [10] [11] Injection of IL-18 restored the IFN-production in response to LPS in the caspase-1-deficient mice, 9 further supporting the concept that caspase-1 is involved in the production of active IL-18. Other caspases, particularly those cleaving intracellular proteins associated with apoptosis, were at least 100-fold less active than caspase-1. 9 Similar studies with IL-18-deficient mice revealed its role in NK cell activity and cytokine induction. 12 A caspase-1-independent pathway of IL-18 secretion from FasL-stimulated macrophages was recently demonstrated, suggesting that FasL may induce alternative mechanisms for production of IL-18. 13 Unlike mouse IL-18, 2 we noticed that recombinant human IL-18 is poorly active as a co-inducer of IFN-. Low activity of recombinant proteins is usually due to their aberrant folding. We show here that a highly biologically active form of huIL-18 is obtained upon expression of pro-IL-18 in E. coli and its subsequent cleavage to mature IL-18. Hence, correct folding of huIL-18 occurs at the level of pro-IL-18.
RESULTS AND DISCUSSION

Molecular cloning and expression of human pro-IL-18IEGR
It was reported that human IL-18 is biologically active in murine splenocytes. 2 Comparison of murine and human recombinant IL-18 as inducers of IFN-in IL-12-treated murine splenocytes revealed that murine IL-18 was significantly more active than human IL-18 (data not shown). This difference in potency could be due to species specificity. However, a dose-response study of huIL-18 activity in IL-12-treated human peripheral blood mononuclear cells (PBMC) gave very low levels of huIFN-induction compared with murine IL-18 in the mouse splenocyte model. Incorrect folding of the human recombinant IL-18 could account for its observed low activity.
We tested the possibility that correct folding of huIL-18 requires its prior synthesis as pro-IL-18 in E. coli and subsequent cleavage to yield the active cytokine. Since caspase-1 is not readily available, we constructed a pro-IL-18 expression vector in which the caspase-1 cleavage site (amino acids LESD at positions 33-36) was mutated into a factor Xa site (amino acids IEGR). The mutated human pro-IL-18 coding sequence (pro-IL-18IEGR) was constructed by reverse transcription of PBMC RNA, followed by three steps of PCR, using overlapping primers as described in the Materials and Methods section. The resulting 600 bp PCR product (Fig. 1) was ligated into the pGEM-T Easy vector, subcloned and its sequence was verified. To facilitate purification of IL-18, pro-IL-18IEGR was fused in frame to a glutathione-S-transferase (GST) coding sequence. For this purpose, it was excised by EcoR I and BamH I and cloned into the eukaryotic expression vector pGEX-2TK to yield plasmid pGEXpro-IL-18IEGR (Fig. 2) .
Expression of the GST-pro-IL-18IEGR fusion protein was induced by IPTG in E. coli bearing plasmid pGEX-pro-IL-18IEGR. Following induction, a 43 kDa band, corresponding in size to the fusion protein was detected in bacterial extracts by SDS-PAGE (Fig. 3, lanes 5-7) . The 43 kDa protein was also visible in the insoluble fraction of the lysed cells, indicating that not all of the expressed fusion protein was solubilized (not shown). Control GST protein (26 kDa 14 ) was present in extracts of bacteria transformed with the parental plasmid, pGEX-2TK (Fig. 3 , lane 2). As expected, the 43 kDa fusion protein was specifically bound to glutathione-agarose (Fig. 4 , lane 2).
Purification of GST-pro-IL-18IEGR and production of mature human IL-18
The GST-pro-IL-18IEGR fusion protein was captured from its crude bacterial extract with glutathioneagarose beads. Following extensive washing, the beads were digested with factor Xa and the supernatant was analysed by SDS-PAGE for the presence of mature huIL-18. Two protein bands were detected; a major band of 18 kDa and a minor band of 19.5 kDa (Fig. 5 , lane 2). Protein sequence analysis of the electroblotted 18 kDa and the 19.5 kDa bands demonstrated that their N-terminal sequence matched with that of mature human IL-18. Analysis of these proteins by mass spectrometry gave identical molecular mass, corresponding to that of human IL-18. Therefore, the apparent molecular size heterogeneity of huIL-18 in this preparation may be attributed to alternative folding patterns of the polypeptide backbone. No attempt was made to resolve the 18 and 19.5 kDa species of IL-18 prior to bioassay and therefore it remains to be determined if the two forms differ in their biological activity. A 43 kDa band, corresponding to the undigested fusion protein, was still present in This cDNA was cloned and mutated by three steps of PCR using overlapping primers. The lanes are: M, DNA size markers, indicated on the left side; 1, a 498 bp DNA produced by the first PCR; 2, a 551 bp DNA produced by the second PCR; 3, a 600 bp DNA produced by the third PCR, encoding human pro-IL-18IEGR.
the glutathione-agarose beads, indicating incomplete cleavage (data not shown).
Biological activity of mature human IL-18
Initially, an assay based on induction of IFN-in PBMC in the presence of low dose IL-12 was used for comparing the different preparations of human IL-18. In all tests, human IL-18 obtained by cleavage of pro-IL-18 was more active than the one expressed as a mature protein. However, the use of PBMC from different donors gave a broad range of results (data not shown). Therefore, we used human NKO cells for studying the biological activity of human IL-18. Cells were incubated with various preparations of huIL-18 together with 1 ng/ml of huIL-12. Human IL-18 obtained by cleavage of proIL-18 induced IFN-in a dose-dependent manner. When added, e.g., at 20 ng/ ml, it induced 46.8 0.25 ng/ml of IFN-. Two preparations of IL-18, expressed directly as mature proteins and obtained from two independent manufacturers, were significantly less potent. At 20 ng/ml they induced only 3.9 0.21 and 3.3 0.1 ng/ml of IFN-and their dose-response curve was nearly flat even at much higher concentrations ( Fig. 6; P<0.001; n=3) . Involvement of LPS contamination was excluded by the fact that no induction of IFN-was obtained in the absence of IL-12. Furthermore, polymyxin B was added to eliminate any residual LPS from E. coli. 15 The rather low biological activity of human IL-18 expressed in E. coli directly as a mature protein is probably due to incorrect folding of the polypeptide backbone. Human IL-18 differs in this respect from recombinant mouse IL-18, which exhibits high biological activity when expressed in E. coli directly as a mature protein. Our data suggest that for the human cytokine, expression of pro-IL-18 is a prerequisite for correct folding of the polypeptide backbone. Mutation of the caspase-1 site into a factor Xa site had no adverse effect on the overall folding of pro-IL-18 in spite of introducing an opposite charge (Arg36 instead of Asp36). Indeed, Asp 36 is unlikely to interact with other parts of the pro-IL-18 polypeptide, as it must be accessible for interaction with caspase-1. Similarly, fusion of pro-IL-18 at its N-terminus to GST did not adversely affect the overall folding of pro-IL-18 as evident from the substantial biological activity observed following cleavage. Thus, the present study suggests that correct folding of human IL-18 occurs at the pro-IL-18 stage and provides a method for producing purified, biologically active recombinant human IL-18.
MATERIALS AND METHODS
Reagents and cell culture
Human NKO cells, a subclone of NK-92 cells (ATCC CRL-2407) were kindly provided by Howard Young, NCI (Bethesda, MD, USA). Human IL-2 and IL-15 were purchased from Peprotech (Rocky Hills, NJ, USA). Human IL-18, expressed in E. coli as a mature protein, was obtained from two independent manufacturers. LPS (E. coli 055 B5) and polymyxin B were from Sigma (Nes Ziona, Israel). Supernatant of a bacterial sonicate (see Fig. 3 lane 7) was affinitypurified on gluthatione agarose and samples subjected to SDS-PAGE (10% acrylamide). Lane 1, molecular mass markers (in kDa), indicated on the left side. Lane 2, affinity-purified GST-pro-IL-18IEGR. The gel was stained with Coomassie blue.
Peripheral blood mononuclear cells from healthy donors were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin (RPMI-10) in a humidified 5% CO 2 /air mixture at 37 C. NKO cells were similarly cultured in RPMI-10, further supplemented with human IL-15 (50 pg/ml) and human IL-2 (50 pg/ml; supplemented RPMI-10).
Preparation of peripheral blood mononuclear cells (PBMC)
PBMCs were isolated from peripheral blood obtained from a healthy volunteer by Ficoll-Paque PLUS (Amersham Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation. The PBMCs were washed twice with icecold PBS containing 2% FBS and re-suspended at 2.5 10 6 cells/ml in RPMI-10.
RNA extraction and reverse transcription (RT) polymerase chain reaction (PCR)
PBMC in RPMI-10 (2.5 10 6 cells/ml) were stimulated with LPS (1 g/ml) for 3 h at 37 C. Total RNA was extracted from the cells with the TriPure Isolation Reagent (Roche Molecular Biochemicals, Mannheim, Germany). Total RNA 
cDNA cloning of human proIL-18IEGR
We constructed a cDNA encoding a human pro-IL-18 mutant (pro-IL-18IEGR) in which the caspase-1 cleavage site was mutated into a factor Xa cleavage site. For this purpose, the following mutations were introduced into the human pro-IL-18 cDNA: L33I; S35G and D36R, yielding the factor Xa recognition sequence IEGR33-36. The pro-IL-18IEGR cDNA was constructed by a three-step PCR, using the overlapping primer method. The various primers were designed on the basis of the pro-IL-18 sequence (GenBank accession no. D49950
3 ). For the first PCR, the forward primer was: 5 AACAC GAAGGTCGTTACTTTGGCAAGCTTGAATC3 and the reverse primer was 5 CGCGAATTCCTAGTCTTCGTTTT GAACAGT3 . An Eco RI site was included in the reverse primer. The template used was reverse-transcribed total cellular RNA, isolated from the LPS-stimulated PBMC. The thermocycling conditions were: 10 cycles of 94 C, 30 s; 55 C, 30 s; and 68 C, 2 min followed by 25 cycles of 94 C, 30 s; 55 C, 30 s; and 68 C, 125 s/cycle. The resulting 498 bp PCR product was amplified in the second PCR step using the overlapping forward primer: 5 TGGCAATGAAATTTATT GACAATACGCTTTACTTTATAGCTGAAGATGATGA AAACATCGAAGGTCGTTACTTTG3 , and the reverse primer of the previous step. The thermocycling conditions were: 30 cycles of 94 C, 30 s; 56 C, 30 s and 72 C, 1 min. The GST-pro-IL-18IEGR fusion protein captured on glutathione agarose beads was incubated with factor Xa at a protease to substrate ratio 1:50 (W/W). After 6 h the supernatant was collected and an aliquot analysed by SDS-PAGE (12% acrylamide). Lane 1, molecular weight markers (in kDa), indicated on the left side. Lane 2, human IL-18 released into the supernatant of the glutathioneagarose beads. The gel was stained with Coomassie blue. Human IL-18 produced directly in E. coli as a mature cytokine ( , , two independent suppliers) or produced by cleavage of pro-IL-18IEGR ( ) was added at the indicated doses together with human IL-12 (1 ng/ml) and polymyxin B (1 g/ml) to cultures of NKO cells (1 10 6 cells/ml). Human IL-18 produced by cleavage of pro-IL-18IEGR was also added in the absence of IL-12 ( ). After 24 h, the supernatants were assayed for human IFN-by ELISA. The results shown are the mean SEM (n=3). All errors were less than 1%. See text for statistics. resulting 551 bp product was amplified in the third step using the overlapping forward primer: 5 CGTGGATCCATGGC TGCTGAACCAGTAGAAGACAATTGCATCAACTTTG TGGCAATGAAATTTATTGAC3 and the reverse primer of the previous steps. A BamH I site was included in the forward primer. The thermocycling conditions were the same as those of the previous step. The resulting 0.6 kb PCR product was purified using the High Pure PCR product purification kit (Roche Molecular Biochemicals) and ligated into the pGEM-T Easy Vector (Promega Corporation, Madison, WI, USA) to yield plasmid pGEM-pro-IL-18IEGR. Ligation products were transformed into JM109 competent cells (Promega). The DNA sequence of the insert in pGEM-pro-IL-18IEGR was confirmed by automated DNA sequencing. Standard cloning protocols were used throughout.
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Construction of a pro-IL-18IEGR expression plasmid
Plasmid pGEM-pro-IL-18IEGR from a single colony was verified for the presence of a correct insert by restriction enzyme digestion and DNA sequencing. The plasmid was digested with BamH I and EcoR I. The resulting BamH I/ EcoR I DNA encoding human pro-IL-18IEGR was resolved by electrophoresis in 1.0% agarose and the 0.6 kb band was isolated from the gel by a QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). This DNA was ligated into the pGEX-2TK expression vector (Amersham Pharmacia Biotech) which was linearized with BamH I and EcoR I. The resulting recombinant plasmid pGEX-pro-IL-18IEGR was transformed into E. coli (JM109 strain) and the resulting vector was confirmed by restriction enzyme digestion and nucleic acid sequencing.
Expression and purification of GST-pro-IL-18IEGR fusion protein
Expression and purification of GST-pro-IL-18IEGR was performed essentially as described. 14, 17 In brief, a 50 ml overnight culture from a fresh single colony of E. coli JM109 transformed with plasmid pGEX-pro-IL-18IEGR was diluted in 450 ml LB medium containing 100 U/ml ampicillin and grown with shaking at 37 C, until reaching a density of 0.6 OD 600 . Protein expression was then induced by adding IPTG to a final concentration of 0.1 mM and further incubation of the culture at 37 C for 3 h. For analysis of total bacterial protein, an aliquot of the bacterial culture was pelleted in a microcentrifuge, boiled in 1 sample buffer (50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% SDS, 10% glycerol, 0.01% bromophenol blue) and resolved by 0.1% SDS-10% polyacrylamide gel electrophoresis followed by Coomassie blue staining. 18 For preparation of mature huIL-18, bacteria were harvested by centrifugation (5000 g, 5 min, 4 C) and rapidly re-suspended in a 1:100 starting volume of ice-cold phosphate-buffered saline (PBS; 150 mM NaCl, 16 mM Na 2 HPO 4 , 4 mM NaH 2 PO 4 , pH 7.3), containing protease inhibitors (leupeptin 1 g/ml, pepstatin A 1 g/ml, aprotinin 2 g/ml, PMSF 0.2 mM and EDTA 5 mM). Cells were lysed on ice by mild sonication (4 15 s bursts). Triton X-100 was added to a final concentration of 1% and the mixture kept on ice for 5 min. The clarified lysate (14 000 g, 15 min, 4 C) was mixed with a 50% suspension of glutathione-agarose beads (2 ml, Amersham Pharmacia Biotech) and the mixture was incubated with mild shaking at 4 C for 3 h. The beads were pelleted by centrifugation (500 g, 5 min), washed twice with ten volumes of lysis buffer (1% Triton X-100 in PBS), twice with ten volumes of 20 mM Tris-HCl, pH 8.0, twice with ten volumes of 20 mM Tris-HCI, pH 8.0, 150 mM NaCl, and twice with ten volumes of 20 mM Tris-HCI, pH 8.0, 150 mM NaCl, 2.0 mM CaCl 2 (Cleavage Buffer). All steps were performed at 4 C.
Cleavage of the fusion protein and purification of mature human IL-18
The glutathione-agarose beads with bound GST-pro-IL-18 IEGR fusion protein were incubated (6 h, 23 C) with factor Xa (New England Biolabs, Beverly, MA, USA) in 1 ml Cleavage Buffer, at a protease to substrate ratio of 1:200 (W/W), with constant mixing on a rotating wheel. This step releases the mature human IL-18. The beads were pelleted by centrifugation at 500 g for 5 min at 4 C and washed five times with 2 ml ice-cold PBS. The supernatant and each of the washes were combined, clarified by centrifugation (14 000 g, 15 min, 4 C) and concentrated by ultrafiltration (Centricon-10, Amicon, Beverly, MA, USA). Aliquots of the eluate, as well as beads before and after digestion, were resolved by 0.1% SDS-10% polyacrylamide gel electrophoresis followed by Coomassie blue staining. N-terminal protein sequence analysis was performed on individual protein bands, obtained by SDS-PAGE (12% acrylamide, under reducing conditions), followed by electroblotting to a PVDF membrane. The purified protein was sterilized through a 0.2 m filter and stored at 70 C.
Bioassay of human IL-18
Human NKO cells produce IFN-upon co-stimulation with IL-12 and IL-18 (Young, H., manuscript in preparation and ref. 19 ). Hence, the biological activity of human IL-18 from various sources was assessed by its ability to induce IFN-in human NKO cells in the presence of IL-12. Briefly, NKO cells in supplemented RPMI-10 (1 10 6 cells/ml) were seeded in 96-well culture plates at 200 l/well. Human IL-12 (1 ng/ml final concentration) and polymyxin (1 g/ml) were added to the wells together with various doses of human IL-18 (final volume 250 l). The cultures were incubated for 24 h at 37 C in 5% CO 2 and the supernatants were then assayed for huIFN-by a sandwich-type ELISA with two monoclonal antibodies to huIFN-(Nos. 3.3 and biotinlabelled-166.5 20 ).
